These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16523950)

  • 21. [CME. Fabry disease: rare but not to be missed].
    Steinack C; Gaspert A; Kovacs R; Nowak A
    Praxis (Bern 1994); 2015 Jul; 104(14):719-29. PubMed ID: 26135721
    [No Abstract]   [Full Text] [Related]  

  • 22. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
    Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
    J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
    Ziegler RJ; Yew NS; Li C; Cherry M; Berthelette P; Romanczuk H; Ioannou YA; Zeidner KM; Desnick RJ; Cheng SH
    Hum Gene Ther; 1999 Jul; 10(10):1667-82. PubMed ID: 10428212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of recombinant alpha-galactosidase A therapy for amelioration of the cardiovascular manifestations of Fabry disease: an important role for endomyocardial biopsy.
    Buja LM
    Circulation; 2009 May; 119(19):2539-41. PubMed ID: 19451361
    [No Abstract]   [Full Text] [Related]  

  • 25. Fabry disease.
    Schiffmann R
    Pharmacol Ther; 2009 Apr; 122(1):65-77. PubMed ID: 19318041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spotlight on agalsidase beta in Fabry disease.
    Keating GM; Simpson D
    BioDrugs; 2007; 21(4):269-71. PubMed ID: 17628124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy.
    Ohashi T; Sakuma M; Kitagawa T; Suzuki K; Ishige N; Eto Y
    Mol Genet Metab; 2007 Nov; 92(3):271-3. PubMed ID: 17689998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Guidelines to diagnosis and monitoring of Fabry disease and review of treatment experiences.
    Martins AM; D'Almeida V; Kyosen SO; Takata ET; Delgado AG; Gonçalves AM; Benetti Filho CC; Martini Filho D; Biagini G; Pimentel H; Abensur H; Guimarães HC; Gomes JG; Sobral Neto J; D'Almeida LO; Carvalho LR; Harouche MB; Maldonado MC; Nascimento OJ; Montoril PS; Bastos RV
    J Pediatr; 2009 Oct; 155(4 Suppl):S19-31. PubMed ID: 19765408
    [No Abstract]   [Full Text] [Related]  

  • 29. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.
    Thurberg BL; Fallon JT; Mitchell R; Aretz T; Gordon RE; O'Callaghan MW
    Circulation; 2009 May; 119(19):2561-7. PubMed ID: 19414635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease.
    Wraith JE; Tylki-Szymanska A; Guffon N; Lien YH; Tsimaratos M; Vellodi A; Germain DP
    J Pediatr; 2008 Apr; 152(4):563-70, 570.e1. PubMed ID: 18346516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Priapism: a severe paediatric complication of Fabry disease].
    Labarthe F; de Bodman C; Maruani A; Szwarc C; Froissart R; Lorette G; Lardy H
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S217-9. PubMed ID: 21211667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fabry disease during childhood: clinical manifestations and treatment with agalsidase alfa.
    Ramaswami U
    Acta Paediatr; 2008 Apr; 97(457):38-40. PubMed ID: 18339186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Fabry disease (alpha-galactosidase deficiency)].
    Utsumi K; Sakuraba H
    Ryoikibetsu Shokogun Shirizu; 1998; (19 Pt 2):367-71. PubMed ID: 9645084
    [No Abstract]   [Full Text] [Related]  

  • 34. Anderson-Fabry disease: a protean clinical behavior and a chance diagnosis.
    Amico L; Visconti G; Amato A; Azzolina V; Sessa A; Li Vecchi M
    J Nephrol; 2005; 18(6):770-2. PubMed ID: 16358237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A diagnosis of Fabry gastrointestinal disease by chance: a case report.
    Feriozzi S; Torre ES; Ranalli TV; Cardello P; Morrone A; Ancarani E
    Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):163-5. PubMed ID: 17273003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enzyme replacement therapy in an adolescent with Fabry disease.
    Illsinger S; Luecke T; Langen H; Das AM
    Eur J Pediatr; 2003 Jul; 162(7-8):522-523. PubMed ID: 12733069
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparative evaluation of alpha-galactosidase A infusions for treatment of Fabry disease.
    Hopkin RJ; Bissler J; Grabowski GA
    Genet Med; 2003; 5(3):144-53. PubMed ID: 12792421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
    Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
    Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Consensus for the study and treatment of Fabry disease. GETER Foundation].
    García de Lorenzo A;
    Med Clin (Barc); 2011 Jul; 137(4):178-83. PubMed ID: 21529855
    [No Abstract]   [Full Text] [Related]  

  • 40. [What is new in Fabry disease?].
    Lidove O
    Rev Med Interne; 2007 Dec; 28 Suppl 4():S296-7. PubMed ID: 17964003
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.